CooperVision (NYSE:COO) said that it won FDA approval for its MiSight one-day contact lens for slowing the progression of myopia when initially prescribed for children between 8-12 years old. The San Ramon, Calif.–based company announced the clearance for the first and only FDA-approved product clinically proven to slow myopia (nearsightedness or short-sightedness) yesterday. CooperVision said […]
FDA approves CooperVision’s contact lens to slow nearsightedness in kids
The FDA has approved the first contact lens indicated to slow the progression of nearsightedness in children between the ages of 8 and 12 years old. The MiSight contact by CooperCompanies’ (NYSE:COO) CooperVision lens is a single-use, disposable, soft contact lens that is discarded at the end of each day and is not intended to be worn […]
Ocular Therapeutix dips on Q3 losses
Ocular Therapeutix (NSDQ:OCUL) shares fell today on third-quarter results that narrowly topped the consensus forecast despite a bottom-line dip. The Bedford, Mass.–based ophthalmic insert maker posted losses of -$18,778, or -45¢ per share, on sales of $829,000 for the three months ended Sept. 30, for a 25.1% bottom-line slide on sales growth of 66.5%. Adjusted to […]
Glaukos slides on Q3 profit drop
Glaukos (NYSE:GKOS) shares dropped today on third-quarter earnings that topped the consensus forecast despite sliding profits. The San Clemente, Calif.-based ophthalmic medical technology and pharmaceutical company posted losses of -$13.5 million, or -37¢ per share, on sales of $58.5 million for the three months ended Sept. 30, for a large bottom-line slide on sales growth of […]
Regenxbio pulls trigger on option to license Clearside Biomedical’s SCS Microinjector
Clearside Biomedical (NSDQ:CLSD) said yesterday that Regenxbio (NSDQ:RGNX) exercised its option to license Clearside’s in-office SCS Microinjector for delivering adeno-associated virus (AAV)-based therapeutics in treating wet age-related macular degeneration, diabetic retinopathy and other conditions. The two companies inked the option and licensing deal that they said at the time could be worth more than $130 million on […]
Clearside Biomedical inks $76m licensing deal with Bausch for Xipere
Clearside Biomedical (NSDQ:CLSD) said yesterday that it entered into a license agreement with Bausch Health Ireland (NYSE:BHC) worth up to $76 million for the Xipere device for the treatment of macular edema associated with uveitis. The agreement grants Bausch an exclusive license to develop, manufacture, distribute, promote, market and commercialize the suprachoroidal injection device. Get the full […]
Ocean Insight, Triple Ring ink deal
Optical sensing company Ocean Insight said today it has formed a strategic partnership with medtech and imaging systems manufacturer Triple Ring Technologies. Ocean Insight specializes in spectral technology, application and manufacturing scalability for biomedical, life sciences and other companies. It has locations in the Americas, Europe and Asia and is part of global medtech company Halma plc. The partnership with Triple Ring adds expertise […]
Clearside Biomedical confirms timeline for Xipere
Clearside Biomedical (NSDQ:CLSD) last week said that the FDA found no efficacy issues with its Xipere drug-delivery technology and will not ask for further clinical efficacy studies. The Xipere device is a suprachoroidal injection designed for the treatment of macular edema associated with uveitis. In October 2018, Clearside touted data from a Phase III pivotal trial, which reported […]
IBM Watson to pull the plug on Merge Eye
UPDATED with a clarification from IBM Watson Health. Topcon Healthcare Solutions said today that it is a preferred vendor for IBM Watson Health Imaging in support of a transition plan for the Merge Eye imaging platform. IBM Watson plans to discontinue customer support for the Merge Eye Station digital fundus imaging platform and the Merge […]
Myra Medical raises $3m seed round, lures ex-MVRx chief Chang as new CEO
Newly formed Shifamed spinout Myra Medical said today that it closed a seed financing round worth $3.2 million and announced the appointment of Robert Chang as CEO. Campbell, Calif.-based Myra Medical was founded to produce surgical devices designed to enable maximum intraocular pressure reduction while reducing the risk of hypotony in patients with glaucoma. Proceeds […]
OcuMedic, Gelest ink drug-delivering contact lens deal
OcuMedic said today that it entered into an exclusive supply agreement and picked up a strategic investment from Gelest for its proprietary drug-eluting soft contact lens of an undisclosed amount. Under the terms of the agreement, Morrisville, Pa.-based Gelest is set to manufacture and supply OcuMedic’s key chemistry components used in the controlled release of […]
- 1
- 2
- 3
- …
- 71
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube